Regis College is now offering master’s and certificate programs in regulatory and clinical research management (RCRM). This program is designed for individuals who wish to start or advance a career in the regulation of pharmaceuticals, devices, biologics, and health care technology, or in clinical research management. The first student cohort begins in May.
As with other programs within the university’s School of Health Sciences, students in the RCRM program are provided an education that fosters the students’ capacity to gain knowledge, develop content specific skills and overall professional skills, and enhance their career goals. The master of science in RCRM program allows students to begin or advance a career in the increasingly complex and growing areas of commercialization of pharmaceuticals, medical device products, biologics, regulatory affairs, and clinical trial operations, compliance, and management.
“Graduates from Regis’ master’s and certificate programs in regulatory and clinical research management will be prepared to make substantive contributions to the development and advancement of medical products for some of the biggest companies and agencies in the world. The program conveys the skills necessary for future regulatory affairs and clinical research professionals to excel in the field,” said Provost and Vice President of Academic Affairs Mary Erina Driscoll, PhD.
Students can choose from two specialty tracks: regulatory affairs and clinical research management. While earning an MS-RCRM degree, students will develop knowledge to work toward professional certification goals such as: Regulatory Affairs Certification (RAC), Association of Clinical Research Professionals (ACRP), and Project Management Certification (PMI).
Additionally, every student in the program receives real-world experience allowing them to apply classroom learning in a professional setting to develop skills, learn from professionals in the field, and build your professional network. Recent practicum placements include Genzyme, Nova Biomedical, Tesaro Pharmaceuticals, and Takeda Pharmaceuticals.